window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 14, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Cell Therapy

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    ARTCLINE completes enrolment in septic shock trial for ARTICE therapy

    ARTCLINE has completed patient enrolment in a 142-patient randomized study [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development

    MaxCyte launches 96-well electroporation platform for cell therapy discovery

    MaxCyte, Inc. has launched ExPERT DTx, a 96-well electroporation platform [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Kidswell Bio and Treehill Partners launch US newco to advance cell therapy for paediatric cerebral palsy

    Kidswell Bio and Treehill Partners have launched a US-based regenerative [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Hans Schambye appointed as CEO of BOOST Pharma as BT‑101 advances toward Phase 3

    BOOST Pharma has appointed Hans Schambye as its new chief [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    iOrganBio appoints Karol Jarzabek as chief operating officer

    iOrganBio has appointed Karol Jarzabek as chief operating officer to [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    CERo reports early safety signals and platelet transfusion-free interval in Phase 1 AML trial

    CERo Therapeutics has reported early clinical findings from its ongoing [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Opinion & Events

    ICON 2025 global biotech survey shows China leading innovation and highlights Western opportunities

    ICON plc has released findings from its 2025 global biotech [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Cue Biopharma and ImmunoScape partner on novel in vivo cell therapy for solid tumours

    Cue Biopharma and ImmunoScape have entered an exclusive collaboration and [...]

    May 5, 2026
  • Advanced Therapies,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    NurExone joins ARMI BioFab Startup Lab to boost US regenerative manufacturing

    NurExone Biologic Inc has been accepted into the BioFab Startup [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Therapeutic Areas

    Minovia Therapeutics gains FDA orphan drug designation for MNV-201 in myelodysplastic syndrome

    Minovia Therapeutics has received orphan drug designation from the US [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • NETRIS Pharma Nature publishes pancreatic cancer Phase 1b data showing NP137 survival and surgery gains
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Therapeutic Areas
  • Myomaker Bio launches lab-grown human muscle platform for preclinical drug testing
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development
  • Abivax to present nine obefazimod studies at DDW as Phase 3 ulcerative colitis data build
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Opinion & Events, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top